Tau Biosensor Cell Lines for Attomolar Protein Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack sensitivity and reliability for detecting tau protein seeding activity in peripheral fluids, such as cerebrospinal fluid (CSF), which is crucial for early diagnosis of Alzheimer's disease and other tauopathies, as existing technologies cannot reliably detect the smallest amounts of tau protein seeds.
Innovation Solution
Development of polynucleotides, expression cassettes, vectors, and biosensor cells that express tau repeat domains with reporter proteins, enabling the detection of attomolar levels of seed tau protein through fluorescence resonance energy transfer (FRET) assays, allowing for the measurement of tau protein titers and identification of tau protein aggregation inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used, then the detection process is simple, but the sensitivity and reliability of tau protein detection are insufficient
Solution Approach 1:
The patent introduces reporter proteins (such as fluorescent proteins) as intermediaries that bind to tau protein seeds. These reporters act as mediators between the target tau seeds and the detection system, amplifying the signal and enabling sensitive detection of attomolar levels of tau protein in complex biological fluids like CSF and blood.
Solution Approach 2:
The patent replaces conventional mechanical or chemical detection methods with a biological sensing system using engineered cell lines that express tau-repeat domain-fused reporter proteins. This biological substitution enables highly sensitive detection through cellular uptake and intracellular aggregation events, achieving detection limits of attomolar concentrations.
2Measurement precision
If existing detection technologies are used, then the detection method is established, but they cannot reliably detect the smallest amounts of tau protein seeds
Solution Approach 1:
The patent performs preliminary action by engineering cell lines to pre-express tau-repeat domain-fused reporter proteins before exposure to sample fluids. This pre-preparation ensures that when tau seeds are introduced, the cells are immediately equipped with the necessary sensing machinery, enabling rapid and reliable detection at attomolar levels without requiring complex sample preparation or incubation steps.
3Loss of time
If high sensitivity detection is achieved, then early diagnosis is enabled, but the detection system becomes more complex
Solution Approach 1:
The patent implements self-service by designing autonomous biosensor cell lines that internally perform all necessary detection functions. The engineered cells autonomously take up tau seeds from the sample, process them intracellularly, and generate detectable signals through reporter protein aggregation, eliminating the need for complex external instrumentation or multiple processing steps and enabling rapid diagnosis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described method significantly enhances the sensitivity of tau protein detection, enabling the reliable identification of seed tau protein at attomolar levels, facilitating early diagnosis and the discovery of therapeutic agents that can interfere with tau protein replication.
Implementation Method 1
enabling the detection of attomolar levels of seed tau protein through fluorescence resonance energy transfer (FRET) assays
Data Source
AI summary
The present disclosure provides biosensor cells and methods of use thereof. The disclosure provides, for example, methods of measuring a titer of or of detecting a seed tau protein in a sample, methods of detecting Alzheimer's disease (AD), or a neurodegenerative tauopathy disease or condition linked to tau protein aggregation, and methods for the identification of putative tau protein aggregation inhibitors or modulators.